NCT01443078View on ClinicalTrials.gov

Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions

Lung Cancer

Interventions

DRUG

pemetrexed

DRUG

cisplatin

DRUG

Carboplatin

DRUG

Gemcitabine Hydrochloride

DRUG

Vinorelbine Tartrate

DRUG

Docetaxel

Trial Locations (5)

10065

Memorial Sloan Kettering Cancer Center, New York

10591

Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center, Sleepy Hollow

11725

Memorial Sloan-Kettering Cancer Center @ Suffolk, Commack

Unknown

Memoral Sloan Kettering Cancer Center, Basking Ridge

Memorial Sloan-Kettering at Mercy Medical Center, Rockville Centre

All Listed Sponsors

collaborator

Eli Lilly and Company

INDUSTRY

collaborator

United States Department of Defense

FED

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT01443078 - Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN) | Biotech Hunter | Biotech Hunter